FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319080293> ?p ?o ?g. }

• W4319080293 abstract "Metastatic castration-resistant prostate cancer remains a challenging condition to treat. Among the available therapeutic options, the androgen receptor signaling inhibitors abiraterone acetate plus prednisone (AA) and enzalutamide (Enza), are currently the most used first-line therapies in clinical practice. However, validated clinical indicators of prognosis in this setting are still lacking. In this study, we aimed to evaluate a prognostic model based on the time of metastatic disease presentation (after prior local therapy [PLT] or de-novo [DN]) and disease burden (low volume [LV] or high-volume [HV]) at AA/Enza onset for mCRPC patients receiving either AA or Enza as first-line.A cohort of consecutive patients who started AA or Enza as first-line treatment for mCRPC between January 1st, 2015, and April 1st, 2019 was identified from the clinical and electronic registries of the 9 American and European participating centers. Patients were classified into 4 cohorts by the time of metastatic disease presentation (PLT or DN) and volume of disease (LV or HV; per the E3805 trial, HV was defined as the presence of visceral metastases and/or at least 4 bone metastases of which at least 1 out the axial/pelvic skeleton) at AA/Enza onset. The endpoint was overall survival defined as the time from AA or Enza initiation, respectively, to death from any cause or censored at the last follow-up visit, whichever occurred first.Of the 417 eligible patients identified, 157 (37.6%) had LV/PLT, 87 (20.9%) LV/DN, 64 (15.3%) HV/PLT, and 109 (26.1%) HV/DN. LV cohorts showed improved median overall survival (59.0 months; 95% CI, 51.0-66.9 months) vs. HV cohorts (27.5 months; 95% CI, 22.8-32.2 months; P = 0.0001), regardless of the time of metastatic presentation. In multivariate analysis, HV cohorts were confirmed associated with worse prognosis compared to those with LV (HV/PLT, HR = 1.87; p = 0.029; HV/DN, HR = 2.19; P = 0.002).Our analysis suggests that the volume of disease could be a prognostic factor for patients starting AA or Enza as first-line treatment for metastatic castration-resistant prostate cancer, pending prospective clinical trial validation." @default.
• W4319080293 created "2023-02-04" @default.
• W4319080293 creator A5006746061 @default.
• W4319080293 creator A5009277251 @default.
• W4319080293 creator A5017866134 @default.
• W4319080293 creator A5031841195 @default.
• W4319080293 creator A5032943515 @default.
• W4319080293 creator A5036125918 @default.
• W4319080293 creator A5036946878 @default.
• W4319080293 creator A5047133719 @default.
• W4319080293 creator A5053905496 @default.
• W4319080293 creator A5057926104 @default.
• W4319080293 creator A5063785560 @default.
• W4319080293 creator A5064026892 @default.
• W4319080293 creator A5071060598 @default.
• W4319080293 creator A5074461929 @default.
• W4319080293 creator A5078631166 @default.
• W4319080293 creator A5081355165 @default.
• W4319080293 creator A5083659627 @default.
• W4319080293 creator A5089327773 @default.
• W4319080293 date "2023-02-03" @default.
• W4319080293 modified "2023-09-27" @default.
• W4319080293 title "Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer" @default.
• W4319080293 cites W2137467802 @default.
• W4319080293 cites W2166918329 @default.
• W4319080293 cites W2178183066 @default.
• W4319080293 cites W2742524954 @default.
• W4319080293 cites W2999047517 @default.
• W4319080293 cites W3123578364 @default.
• W4319080293 cites W3185713940 @default.
• W4319080293 cites W4226077044 @default.
• W4319080293 cites W4286295787 @default.
• W4319080293 doi "https://doi.org/10.1186/s12967-022-03861-2" @default.
• W4319080293 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36737752" @default.
• W4319080293 hasPublicationYear "2023" @default.
• W4319080293 type Work @default.
• W4319080293 citedByCount "0" @default.
• W4319080293 crossrefType "journal-article" @default.
• W4319080293 hasAuthorship W4319080293A5006746061 @default.
• W4319080293 hasAuthorship W4319080293A5009277251 @default.
• W4319080293 hasAuthorship W4319080293A5017866134 @default.
• W4319080293 hasAuthorship W4319080293A5031841195 @default.
• W4319080293 hasAuthorship W4319080293A5032943515 @default.
• W4319080293 hasAuthorship W4319080293A5036125918 @default.
• W4319080293 hasAuthorship W4319080293A5036946878 @default.
• W4319080293 hasAuthorship W4319080293A5047133719 @default.
• W4319080293 hasAuthorship W4319080293A5053905496 @default.
• W4319080293 hasAuthorship W4319080293A5057926104 @default.
• W4319080293 hasAuthorship W4319080293A5063785560 @default.
• W4319080293 hasAuthorship W4319080293A5064026892 @default.
• W4319080293 hasAuthorship W4319080293A5071060598 @default.
• W4319080293 hasAuthorship W4319080293A5074461929 @default.
• W4319080293 hasAuthorship W4319080293A5078631166 @default.
• W4319080293 hasAuthorship W4319080293A5081355165 @default.
• W4319080293 hasAuthorship W4319080293A5083659627 @default.
• W4319080293 hasAuthorship W4319080293A5089327773 @default.
• W4319080293 hasBestOaLocation W43190802931 @default.
• W4319080293 hasConcept C121608353 @default.
• W4319080293 hasConcept C126322002 @default.
• W4319080293 hasConcept C143998085 @default.
• W4319080293 hasConcept C203092338 @default.
• W4319080293 hasConcept C2775832370 @default.
• W4319080293 hasConcept C2776551883 @default.
• W4319080293 hasConcept C2777899217 @default.
• W4319080293 hasConcept C2778720950 @default.
• W4319080293 hasConcept C2779134260 @default.
• W4319080293 hasConcept C2780192828 @default.
• W4319080293 hasConcept C535046627 @default.
• W4319080293 hasConcept C61367390 @default.
• W4319080293 hasConcept C71924100 @default.
• W4319080293 hasConceptScore W4319080293C121608353 @default.
• W4319080293 hasConceptScore W4319080293C126322002 @default.
• W4319080293 hasConceptScore W4319080293C143998085 @default.
• W4319080293 hasConceptScore W4319080293C203092338 @default.
• W4319080293 hasConceptScore W4319080293C2775832370 @default.
• W4319080293 hasConceptScore W4319080293C2776551883 @default.
• W4319080293 hasConceptScore W4319080293C2777899217 @default.
• W4319080293 hasConceptScore W4319080293C2778720950 @default.
• W4319080293 hasConceptScore W4319080293C2779134260 @default.
• W4319080293 hasConceptScore W4319080293C2780192828 @default.
• W4319080293 hasConceptScore W4319080293C535046627 @default.
• W4319080293 hasConceptScore W4319080293C61367390 @default.
• W4319080293 hasConceptScore W4319080293C71924100 @default.
• W4319080293 hasIssue "1" @default.
• W4319080293 hasLocation W43190802931 @default.
• W4319080293 hasLocation W43190802932 @default.
• W4319080293 hasLocation W43190802933 @default.
• W4319080293 hasOpenAccess W4319080293 @default.
• W4319080293 hasPrimaryLocation W43190802931 @default.
• W4319080293 hasRelatedWork W1203431419 @default.
• W4319080293 hasRelatedWork W1902440608 @default.
• W4319080293 hasRelatedWork W2113899328 @default.
• W4319080293 hasRelatedWork W2309274182 @default.
• W4319080293 hasRelatedWork W2431521472 @default.
• W4319080293 hasRelatedWork W2488918559 @default.
• W4319080293 hasRelatedWork W2805553258 @default.
• W4319080293 hasRelatedWork W2942985299 @default.
• W4319080293 hasRelatedWork W3161788990 @default.
• W4319080293 hasRelatedWork W3202359850 @default.
• W4319080293 hasVolume "21" @default.

• next